Drugs / SEP-631
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07069036 | Jul → Dec 2025 | — | Septerna, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEP-631 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07069036 ↗ |
| Route | Oral | “Oral, tablet” NCT07069036 ↗ |